Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Soluble urokinase plasminogen activator receptor (suPAR) is lower in disease-free patients but cannot rule out incident disease in patients with suspected cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Influence of sample centrifugation on plasma platelet count and activated partial thromboplastin time using patient samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Is a discard tube necessary, when drawing blood for P-Ionized calcium analysis?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Blocking of efflux transporters in rats improves translational validation of brain radioligands

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Renal 123I-MIBG Uptake before and after Live-Donor Kidney Transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Differences in mortality in patients undergoing surgery for infective endocarditis according to age and valvular surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Accurate first-line diagnostics are essential for early recognition of cancer but also to identify patients free of disease. The biomarker soluble urokinase plasminogen activator receptor (suPAR) is elevated in patients with cancer or non-malignant disease compared to disease-free patients. We tested if low suPAR could be used to identify disease-free patients in an accelerated cancer diagnostics program, including ruling out cancer.

METHODS: Patients with serious nonspecific symptoms and signs of cancer (NSSC) were included at the Diagnostic Outpatient Clinic, Copenhagen University Hospital Hvidovre, Denmark. Data from a clinical examination, including blood tests and imaging, was combined with national registry data on diagnoses and mortality. The association between blood suPAR and the primary outcome of disease-free (i.e., absence of incident disease and mortality) within 1-year follow-up was analysed with logistic regression analysis.

RESULTS: Of 1,583 patients included, 349 (22.0%) were diagnosed with cancer, 837 (52.9%) with non-malignant disease, and 392 (25.8%) were disease-free within one year. Admission suPAR was significantly lower in disease-free patients compared to patients with cancer or non-malignant disease (P<0.001), area under the curve 0.67 (95% confidence interval (CI): 0.64-0.70). The highest positive predictive value (PPV) for the outcome of disease-free was 0.55 (95% CI: 0.41-0.68) at a suPAR of 1.65 ng/mL. Patients who died had significantly higher suPAR compared to patients who survived in all disease subgroups. The AUC of suPAR for 1-year mortality was 0.80 (95% CI: 0.77-0.83).

CONCLUSIONS: suPAR was significantly lower in disease-free individuals compared to patients with cancer or other conditions, but the PPV was not sufficiently high to terminate further clinical investigation with appropriate safety. Elevated suPAR may be a useful prognostic marker for adverse outcomes.

OriginalsprogEngelsk
TidsskriftClinical Biochemistry
Vol/bind84
Sider (fra-til)31-37
Antal sider7
ISSN0009-9120
DOI
StatusUdgivet - okt. 2020

ID: 60005205